800 studies found for:    "Hypercholesterolemia"
Show Display Options
Download search resultsDownload the search results for:
"Hypercholesterolemia" (800 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
2 Completed An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: Mipomersen Sodium
3 Completed Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity.
Conditions: Familial Hypercholesterolemias;   Weight Loss;   Familial Combined Hypercholesterolemia;   Obesity
Intervention: Behavioral: Weight loss and dietary intervention
4 Completed
Has Results
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions: Drug: mipomersen;   Drug: Placebo
5 Completed Polish Survey on the Efficacy of the Hypercholesterolemia Treatment
Condition: Hypercholesterolemia
Intervention:
6 Recruiting A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
Conditions: Hypercholesterolemia;   Heterozygous Familial Hypercholesterolemia
Interventions: Drug: EZ 10 mg/Atorva 20 mg FDC;   Drug: EZ 10 mg/Atorva 10 mg FDC
7 Completed Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
8 Terminated
Has Results
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
Conditions: Hypercholesterolemia, Familial;   Heterozygous Familial Hypercholesterolemia
Intervention: Drug: MK-0524A
9 Completed
Has Results
Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Intervention: Drug: Pitavastatin
10 Completed Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention: Drug: MD-0727
11 Withdrawn Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Interventions: Biological: Placebo;   Biological: 1 mg/kg every 2 weeks;   Biological: 2 mg/kg every 4 weeks;   Biological: 4 mg/kg every 4 weeks;   Biological: 4 mg/kg every 8 weeks;   Biological: 8 mg/kg every 8 weeks;   Biological: 12 mg/kg every 8 weeks
12 Completed Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Intervention: Biological: PF-04950615 (RN316)
13 Completed Pan-European Survey on the Under Treatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
14 Recruiting Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Conditions: Familial Hypercholesterolemia;   Lipid Disorder
Intervention:
15 Recruiting Study of Awareness and Detection of Familial Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
16 Completed Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
17 Completed Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
Conditions: Hypercholesterolemia;   Cardiovascular Disease;   Hypertension;   Diabetes;   Coronary Heart Disease;   Peripheral Arterial Disease
Intervention:
18 Completed Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
Condition: Familial Hypercholesterolemia
Intervention: Drug: lomitapide
19 Completed Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States
Condition: Hypercholesterolemia
Intervention:
20 Unknown  Effect of Plant Sterols on the Lipid Profile of Patients With Hypercholesterolaemia
Condition: Hypercholesterolemia
Intervention: Dietary Supplement: Plant stanol esters

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years